Member Info for BuenaVista

Don't worry notrex, CC will have her own loyal support in place soon enough - or she won't be effective as CEO.

Does it do any good to rake up the details of that disastrously priced placing when those responsible, AS and TG*, have gone? Doing so wouldn't change anything as changes (will) have been made already. It could only be for the morbid curiosity of people not privy to what still might be confidential or commercially sensitive.

* Assumming TG's days can be counted on digits.

Chief Scientific Officer - chemistry, pharmacology, pre-clinical development

Chief Medical Officer - clinical development

Chief Financial Officer replacement

I wasn't expecting any information about the 'European specialist healthcare fund' (aka AXA Framlington Biotech) as Avacta have no right to disclose what the fund is, nor about Q2W cohort 1 as there was nothing about it in today's RNS, but I wasn't expecting CC to duck questions about the 50p placing. Clearly it was arranged in advance so that all the questions about the placing could be lost in the questions about strategy.

As a warm-up act, you've just died and disappeared behind the curtain kat.

Anyone know what time the main attraction is on?

So you'll now refuse all medications. Fine. Your choice. Maybe toddle off and get some more DJT stock when the market opens?

You know kat, there are wonderfully effective drugs for all sorts of mental conditions.

I'm intrigued kat. Tell me more about Avacta's covid mRNA vaccine adventure.

I'll be glad to see it limp over 50p for starters.

Ah, the old ones are the best! "Potential" - one of the classics.

Oh very Tap!

So what are AVA6000's clinical advantages kat?

🤣🤣🤣 kat knows how to find the Avacta website!!!!

🤡

So what is the lead asset? What are its clinical advantages? Those are simple questions. If you don't know the answers, you know nothing about this company and your opinions are less than worthless.

Kat, what do you know about this company? Tell us about its lead asset.

Everything Alan said can now be disregarded. All change. Let's hear what the new CEO has to say about operational activities and the company's future strategy.

And another one:

With the BoD's commitment to "the need to more clearly communicate with shareholders and other key stakeholders" will Avacta now move to Nasdaq-style quarterly detailed reporting of financial and operational activities.

1. When will Tony Gardiner be replaced

2. Why hasn't Q2W cohort 1 been reviewed by the SDMC as anticipated.

Whilst we may not get answers there and then, if enough of us send in our own versions of these questions at the start of the presentation at least CC will be fully aware of our concerns.

TG now sticks out like a sore thumb as the only remaining one without pharma industry experience. His days are surely numbered. What's CC's email address...

Nice to hear Alan got his lipstick out for Launch. Not long now till Dx is sold off at a loss.

Now there's an idea.